Physician profile
Dan E Dardashti
NPI 1275537524
$1,337.54
in general payments reported to CMS, 2019-2025
17 companies · $74.14 in 2025
The $74.14 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.04 · 2020: $146 · 2021: $312 · 2022: $396 · 2023: $206 · 2024: $179 · 2025: $74.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.05 | 2021-2023 | Ubrelvy |
| Lilly USA, LLC | $290.19 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.73 | 2019-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $99.76 | 2020-2021 | |
| Pfizer INC. | $71.18 | 2020-2025 | |
| Glaxosmithkline, LLC. | $58.47 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $47.08 | 2020 | |
| Novo Nordisk INC | $42.07 | 2021-2023 | Wegovy, Saxenda |
| Dexcom, INC. | $40.16 | 2021 | |
| Idorsia Pharmaceuticals US INC | $35.48 | 2023 | Quviviq |
| Gilead Sciences, INC. | $31.50 | 2023 | |
| Amgen INC. | $27.11 | 2023 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $24.72 | 2022 | |
| Merck Sharp & Dohme LLC | $24.60 | 2020-2021 | |
| Abbott Laboratories | $23.56 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.33 | 2024 | Xifaxan |
| Exact Sciences Corporation | $20.55 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Dardashti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.